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Abstract
Background: The objective of this study was to evaluate the benefits of
administering ketoprofen to cows suffering from active digital dermatitis
(DD).
Methods: 158 cows presented with active DD (M1, M2 or M4.1 stage) were
randomly allocated to either the control or the treatment group. All cows were
treated with topical application of oxytetracycline spray. The treatment group
also received an intramuscular injection of ketoprofen (3 mg/kg, Ketofen 10%,
Ceva Animal Health). Cows were mobility scored just before they were treated
and then again one week later. Information regarding their daily milk produc-
tion was also collected.
Results: Animals in the control group were at 2.57 (95% confidence interval
(CI): 0.82–8.01, p = 0.10) times higher odds to be lame at the second evalua-
tion compared to those that received ketoprofen as well. This was a numeric
but not statistically significant difference. When only cows that were lame
prior to treatment were considered, cows that did not receive ketoprofen were
at 20.20 (95% CI: 1.40–291.29, p = 0.03) higher odds of remaining lame week
post-treatment comparing to cows that did receive ketoprofen. Freshly calved
and lame at enrolment cows in the treatment group produced 58.38 ± 1.85 kg
per day the week after treatment comparing to freshly calved and lame at
enrolment controls that produced 47.89 ± 1.81 kg per day (p < 0.05).
Conclusion: The addition of ketoprofen in the treatment of active DD lesions
may be beneficial for animal welfare and for animal productivity.
INTRODUCTION
Lameness is one of the most significant problems
facing the dairy industry worldwide, having a major
impact on cattle welfare, health and production, and
leading to substantial economic losses.1 Lameness
has been associated with reduced milk yield,2 mas-
titis, and infertility.3 Lameness has been reported to
be prevalent in dairy herds in Europe and North
America.4–6 Within the UK, the mean herd lameness
prevalence was recently found to be 31.8%.7
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Digital dermatitis (DD) is one of the most frequently
recorded diseases associated with lameness in dairy
cattle. Digital dermatitis is an infectious dermatitis of
the digital skin that may be painful to touch. Lesion
appearance varies; the typical DD lesions have been
described as circumscribed, erosive to papilloma-
tous lesions surrounded by a ridge of hyperkeratotic
skin bearing hypertrophied hairs.8,9 Digital dermati-
tis lesions can be classified according to the M-stage
scoring system which is based on the gross appearance
of the lesion10 and broadly divides lesions into active
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lesions (M1, M2 and M4.1) and healing or chronic
lesions (M3 and M4, respectively). The multifactorial
aetiology of digital dermatitis includes many bacterial
pathogens; the most commonly isolated being spiro-
chetes of the Treponema spp.11
Several regimes have been developed for the treat-
ment of DD. A commonly chosen treatment method
in the UK includes the application of an antibiotic
spray topically.12 Non-antibiotic treatments, such as
copper sulphate and iodine, have been proven insuffi-
ciently effective at achieving a cure, though they may
accelerate the recovery rate.13 Many cases treated with
topical antibiotics require repeated treatments.10
Some stages of DD are painful, but there has been
little research to determine the value of including anal-
gesia in the treatment of DD. The use of non-steroidal
anti-inflammatory drugs (NSAIDs) for the treatment of
non-infectious claw horn disruption lesions has been
investigated14,15; however, to the best of our knowl-
edge, there is no evidence regarding their effectiveness
in the treatment of DD.
In spite of the steadily increasing introduction of
routine preventative measures on farms, the preva-
lence of digital dermatitis remains high. Given that DD
is a painful condition, the use of NSAIDs alongside
antibiotic treatment may be justified on welfare and
possibly on economic grounds; however, this is yet to
be proven. The objective of this randomised, positively
controlled study was to explore the potential benefits
of a single administration of ketoprofen when treat-
ing active digital dermatitis lesions. The study’s null
hypothesis was that use of ketoprofen alongside treat-
ment with the topical antibiotic spray will not affect
animals’ mobility and daily milk yield post-treatment.
MATERIALS AND METHODS
Farm selection
A randomised positively controlled trial was approved
by the University of Liverpool research ethics commit-
tee (VREC828). This study was conducted alongside a
larger scale project involving four farms in the North
West of England and North Wales. The selection of the
farms was based on herd size, the proximity to the
University’s Leahurst campus, and farmers’ willing-
ness to participate in the study. Farm 1 housed milk-
ing Holstein cows that were kept in one group regard-
less of production or lactation stage. On farm 2, the
milking cows were split into two groups based on the
stage of lactation and milk yield. The low production
group was grazed during the summer, as were the dry
cows and youngstock. Farms 3 and 4 split their herd
into eight and four groups respectively based on parity
and lactation stages. Footbaths were used on all farms.
Farms 1 and 4 used footbaths of either copper sulphate
or formalin; the frequency on Farm 1 was three times
a week and on Farm 4 it was conducted daily. Farms 2
and 3 used formalin footbaths only; the frequency on
Farm 2 was three times a week and twice daily on Farm
3.
Cow enrolment
Enrolment for this trial occurred from September 2019
to March 2020. Prior to the commencement of this
trial, animals had been assessed for approximately
2 months pre-calving and were scheduled to be re-
assessed again approximately 1 week, 50–100 days and
170–200 days post-calving (termed: fresh, early lac-
tation and late lactation, respectively). Enrolled cows
on either one of the three lactation time points were
separated from their group during milking and were
mobility scored using the UK Agricultural and Horti-
cultural Development Board (AHDB) 0–3 scale scor-
ing method,16 predominantly by a single trained asses-
sor (C. Bedford). Cows were given a score of 0 when
they walked with even weight-bearing and rhythm on
all four feet, and with a flat back; long, fluid strides
were possible. Cows that stepped unevenly (rhythm or
weight-bearing) or had shortened strides were given a
score of 1; affected limb or limbs were not immediately
identifiable in that case. Score 2 cows had an uneven
weight-bearing on a limb or limbs that was immedi-
ately identifiable and/or obviously shortened strides
(usually with an arch to the centre of the back). Score 3
cows were unable to walk as fast as a brisk human pace
and had signs of a score of 2. All cows were examined
for foot lesions in a foot trimming crush. If a DD lesion
was found during the examination, it was macroscop-
ically classified using the modified standardised M
scoring system with six levels.10 The examination and
the lesion scoring were performed by the same per-
son (A. Anagnostopoulos) for all the animals, who also
applied any treatment if needed as is explained below.
Cows presented with what is considered to be an active
DD lesion (M1, M2 or M4.1 stage) were eligible to par-
ticipate in the study. A random sequence of 0 and 1 had
already been prepared for every farm using the Ran-
dom function in Microsoft Office Excel. Only cows that
had not received any systemic analgesic or antibiotics
for at least a week prior to enrolment were eligible to
participate in the study. If the cow was undergoing any
treatment with NSAIDs or antibiotics, it was automati-
cally excluded from the experiment and the lesion was
treated as per the farm’s treatment protocol. Once a
cow was deemed eligible (and only then) the printed
randomisation list was used to determine whether it
was placed in the control or treatment group. Cows
with claw horn disruption lesions were not treated
with NSAIDs on these farms and were not excluded
from the study. The presence of claw horn disruption
lesions (sole haemorrhage, sole ulceration and white
line disease) was recorded and accounted for in multi-
variable regression analysis.
Cows in both groups were treated with topical appli-
cation of an antibiotic spray containing oxytetracy-
cline (Engemycin 25 mg/ml, MSD Animal Health) after
the lesions had been carefully cleaned and dried with
a clean paper towel. Animals in the treatment group
also received an intramuscular injection of ketoprofen
(3 mg/kg, Ketofen 10%; Ceva Animal Health) adminis-
tered in the neck muscles. Treatments for each animal
from both the control and the treatment group were
Veterinary Record 3 of 8
administered by one person, who also performed the
lesion examination. The mobility score assessor was
not involved in treating the cows but was responsible
for updating the farm medical records for the treat-
ment cows. Cows enrolled in the study were mobil-
ity scored again a week later. Since every farm was
visited once weekly, the cows on the study were sep-
arated and mobility was scored by the same asses-
sor alongside the cows selected for the main project.
Rarely, due to changes of the routine for bank holi-
days or vacation, the assessor would visit the farms
alone just to mobility score cows that had to be re-
evaluated after the first week had passed or a substi-
tute assessor would mobility score the enrolled cows.
The mobility assessor did not have the animal records
from the previous week when scoring them for the
second week. In most instances, the assessor would
also have to sort several other cows during the same
session and therefore the possibility that the mobility
scores post-treatment was biased is rather slim; how-
ever, an element of unconscious bias cannot be pre-
cluded with absolute certainty. Farm records such as
calving date, parity and daily milk yield (for 1-week
pre- and 1-week post-enrolment) were collected for all
the cows enrolled in the study.
Statistical analysis
Data were analysed using JMP Pro 14 (SAS Institute
Inc., Cary, NC). Univariable analysis was performed
to evaluate the success of the randomisation process.
The control and treatment groups were compared to
detect differences in days in milk at enrolment, par-
ity, mobility score at enrolment, mobility score asses-
sor, average milk yield at enrolment, presence of sole
ulceration, presence of white line disease, presence of
sole haemorrhage and presence of DD stage M2. Anal-
ysis of variance was used for continuous outcomes.
Chi-square tests were employed for binary or categor-
ical outcomes.
Univariable analyses were undertaken between vari-
ables and the main outcome variables of interest
before multivariable regression models were con-
structed. Parity was fitted in all models as a categor-
ical variable with two levels (1 for primiparous and 2
for multiparous animals). Mobility scores were turned
into a binary variable describing the prevalence of
lameness (animals with a mobility score of 0 or 1 were
classed as not lame (0) and animals with a mobility
score of 2 or 3 were classed as lame1).
A multivariable logistic regression model with the
presence of lameness (defined as a mobility score of 2
or 3) 1-week post-enrolment as an outcome was built.
Explanatory variables originally offered in this model
were: parity, stage of lactation (fresh, early or late lac-
tation), presence of lameness at enrolment, assessor
of mobility, treatment group, farm, presence of M2
stage DD lesion, presence of sole haemorrhage, pres-
ence of white line disease and presence of sole ulcer-
ation. Variables were removed from the model manu-
ally and in a stepwise manner (with the variable with
the highest p-value removed at each step), and only
variables with p < 0.10 (likelihood ratio test) were kept
in the final model. Farm and treatment groups were
kept in the model regardless of their p-value. The Lack
of Fit test was used to evaluate models goodness of
fit and the likelihood ratio test was used to determine
the overall significance of the models. The predictive
ability of the logistic regression model was assessed
with receiver operating characteristic analysis and the
calculated area under the curve. Results from logistic
regression are presented as odds ratios. The p-values
and 95% confidence intervals (CIs) for calculated
odds ratios are Wald based estimates. All compar-
isons between different levels of categorical explana-
tory variables are for the odds of being lame versus the
odds of not being lame 1-week post-enrolment.
A multivariable logistic regression model with the
presence of lameness (defined as a mobility score of
2 or 3) 1-week post-enrolment as an outcome was
also built including only animals that were lame at
enrolment. Only 20 animals were available for this
analysis. Explanatory variables originally offered in
this model were: parity, stage of lactation (fresh, early
or late lactation), presence of lameness at enrolment,
assessor of mobility, treatment group, farm, presence
of M2 stage DD lesion, presence of sole haemorrhage,
presence of white line disease and presence of sole
ulceration. Variables were removed from the model
manually and in a stepwise manner (with the variable
with the highest p-value removed at each step), and
only variables with p < 0.10 (likelihood ratio test) were
kept in the final model. Farm and treatment groups
were kept in the model regardless of their p-value.
A multivariable linear regression model with average
daily milk yield the week post enrolment as an out-
come was also built. The following explanatory vari-
ables were originally offered to the model: parity, stage
of lactation (fresh, early or late lactation), lameness at
enrolment, average daily milk yield the week before
enrolment, farm, presence of M2 stage lesion, pres-
ence of sole haemorrhage, presence of white line dis-
ease and presence of sole ulceration. The stage of
lactation was combined with lameness at enrolment
to create a new variable in the final model (stage
of lactation by lameness at enrolment). Associations
between explanatory variables were also investigated
to identify collinearity between variables. Interaction
terms of interest were also offered to this model (par-
ity by treatment group and stage of lactation by lame-
ness at enrolment by treatment group). Variables and
their interactions were removed from the model man-
ually and in a stepwise manner (with the variable
with the highest p-value removed at each step), and
only variables with p < 0.10 (F-test) were kept in the
final model. Farm and treatment groups were included
in all the models regardless of their p-values. If an
interaction term was found to be significant, then
the individual effects were kept in the final model
whether they were significant or not. Rows with miss-
ing data were not included in the analysis. Residuals by
model predicted values, student residuals, and resid-
uals normal quantile plots were visualised in order to
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T A B L E 1 Summary data for the study population
Treatment Control Enrolled Lame
Enrolled animals Farm 1 4 5 9 3
Farm 2 7 1 8 1
Farm 3 69 53 122 16
Farm 4 10 9 19 1
Parity group 1 21 19 40
Parity group 2 69 49 118
Farm 1 Farm 2 Farm 3 Farm 4











Stage of Lactation N Mean Min Max Std dev
Fresh 34 6.56 1 16 2.94
Early 59 85.98 61 107 12.87
Late 65 185.55 170 221 11.91
Foot Lesions at enrolment N % of total
DD stage M2 84 53.16%
DD stage M1 or M4.1 74 46.83%
Sole ulcer 6 3.80%
White line disease 14 8.86%
Sole haemorrhage 3 1.9%
evaluate the model’s goodness of fit and that assump-
tions of normality and homoscedasticity were met.
Leverage plots (partial-regression residual leverage
plots) for all fixed effects included in the model were
also visualised. For categorical explanatory variables,
results are presented as least squares means (adjusted
means) ± standard error of the mean. Pairwise com-
parisons of least squares means were made using the
Tukey-Kramer Honestly Significant Difference test.
RESULTS
One hundred and fifty-eight cows were enrolled in the
study, 90 cows were enrolled in the treatment group
and 68 were in the control group. Randomisation lists
were prepared for each farm and for the approxi-
mate number of animals we were expecting to enrol in
each farm. We ended up enrolling fewer animals due
to COVID-19 restrictions and this led to unbalanced
T and C groups in two farms. Had we been able to
continue enrolling animals as originally planned, our
groups would have been more balanced. Table 1 shows
summary data for the study population. A total of 310
mobility scoring assessments were performed. Out of
those assessments, 285 were performed by the main
assessor of mobility in the project (C. Bedford) and 25
were performed by substitute assessors (M. Barden,
n = 7; B. E. Griffiths, n = 16 and T. Menka, n = 2).
Among the 158 animals that were enrolled a total of
six were missed for the second mobility scoring assess-
ment (Farm 1, n = 1; Farm 3, n = 4 and Farm 4, n = 1).
This was a result of these animals not being sorted dur-
ing the visit; no culling occurred the week following
treatment.
Univariable statistical analyses performed to check
the randomisation process found no statistically
significant difference between the control and the
treatment group with respect to parity, days in milk,
milk yield at enrolment or daily milk yield the week
before enrolment. Table 2 summarises all the univari-
able analyses that were performed in order to ensure
that the randomisation process was successful. As
previously mentioned, cows eligible for enrolment
were at the fresh, early lactation or late lactation time-
points. No difference was found between the control
and treatment groups regarding the distribution of the
cows in the aforementioned time points. Lameness
prevalence (defined as a mobility score of 2 or 3) within
the control and treatment group was 11.8% and 14.4%
respectively and not statistically different between the
two groups. Likewise, the prevalence of sole ulcers,
sole haemorrhage, white line disease, and the pres-
ence of M2 stage DD was not different between groups.
Univariable analysis showed that 12 out of 65
(18.46%) animals in the control group were lame at
the second evaluation while 10 out of 87 (11.49%)
animals in the treatment group were lame at the
second evaluation (p = 0.23). A multivariable logistic
regression model, using cows being lame or not at
the second evaluation as the outcome variable, was
undertaken; the main results from this model are
presented in Table 3. Variables retained in this model
(with p-values obtained for each variable from the
final multivariable analysis) were: lameness at enrol-
ment (p < 0.001), mobility score assessor (p = 0.028),
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T A B L E 2 Univariable analyses result to check for differences between the treatment and control group regarding parity, days in milk
(DIM), stage of lactation, lameness, sole haemorrhage, sole ulcer, M2 stage digital dermatitis at enrolment, milk yield at enrolment, and
mobility assessment. Parity group 1 refers to primiparous animals while group 2 refers to multiparous animals
Explanatory variable Level Control Group Treatment group p-value
Parity 1 27.94% 23.33% 0.51
2 72.06% 76.67%
Stage of lactation Fresh 23.53% 20% 0.62
Early lactation 39.71% 35.56%
Late lactation 36.77% 44.44%
Sole haemorrhage at enrolment 0 97.06% 98.89% 0.41
1 2.94% 1.11%
Lameness at enrolment 0 88.24% 85.56% 0.62
1 11.77% 14.44%
Sole ulcer at enrolment 0 97.06% 95.56% 0.62
1 2.94% 4.44%
White line disease at enrolment 0 88.24% 93.33% 0.26
1 11.76% 6.67%
DD stage M2 at enrolment 0 45.59% 47.78% 0.79
1 54.41% 52.22%
DIM (±SD) Fresh 6.37 ± 0.74 6.72 ± 0.70 0.73
Early lactation 85.00 ± 2.49 86.81 ± 2.29 0.59
Late lactation 184.84 ± 2.40 186.00 ± 1.90 0.71
Milk Yield (kg/d) at enrolment (±SD) 40.19 ± 12.28 40.63 ± 11.02 0.62
T A B L E 3 Results from multivariable logistic regression model
for outcome: Lameness 1-week post-enrolment. Presented odds
ratios (OR) are for each level against the reference category for the
odds of being lame (mobility score 2 or 3) 1-week post-enrolment;
p-values and 95% confidence intervals (CI) are Wald based
estimates
Explanatory
variable Level Odds Ratio 95% CI p-value
Lameness at
enrolment








1 4.39 0.87–22.24 0.074
0 Reference
Treatment group Control 2.57 0.82–8.01 0.103
treatment Reference
the prevalence of white line disease at enrolment
(p = 0.088), the prevalence of sole ulceration at
enrolment (p = 0.052), treatment or control group
(p = 0.097) and farm (p = 0.258). The odds of a cow
being found lame at the second evaluation were 13.55
(95% CI: 3.46–53.01, p < 0.001) times higher for ani-
mals that were lame at enrolment compared to cows
that were not lame at the time of enrolment. Animals
that only received topical antibiotic treatment were at
2.57 (95% CI: 0.82–8.01, p = 0.103) times higher odds
to be lame at the second evaluation compared to those
that received ketoprofen as well. Cows diagnosed with
sole ulceration or white line disease at the time of
enrolment were at 9.93 (95% CI: 1.15–85.93, p = 0.037)
and 4.39 (95% CI: 0.87–22.24, p = 0.074) times higher
odds of being lame a week post enrolment comparing
to cows not affected by these foot lesions.
When only lame at enrolment animals were con-
sidered, five out of seven (71.43%) lame animals that
were in the control group remained lame a week after
the treatment while four out 13 (30.77%) lame ani-
mals that were in the treatment group remained lame
a week after treatment (p = 0.08, resulted from uni-
variable analysis). Variables that were retained in the
multivariable logistic regression model with lameness
a week post-treatment as an outcome (only for ani-
mals that were also lame at enrolment) were: mobil-
ity score assessor at enrolment (p= 0.092), presence of
sole ulceration at enrolment (p = 0.091), treatment or
control group (p = 0.011) and farm (p = 0.093). Ani-
mals that only received topical antibiotic treatment
were at 20.20 (95% CI: 1.40–291.28, p = 0.027) times
higher odds to be lame at the second evaluation com-
pared to those that received ketoprofen as well. These
results should however be treated with caution as they
are based on data from only 20 animals.
Variables retained in the model with average daily
milk yield for the week post enrolment were: the aver-
age daily milk yield for the week before enrolment
(p < 0.001), stage of lactation by lameness at enrol-
ment (p < 0.001), treatment group (p < 0.01), stage
of lactation by lameness at enrolment by treatment
group (p< 0.001) and farm (p= 0.65). The main results
from this model are presented in Table 4 and Figure 1.
Cows that received ketoprofen did produce more milk
per day the week after treatment than the cows in the
control group with adjusted means (± standard error)
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F I G U R E 1 Results from multivariable linear regression model for outcome mean daily milk yield (kg) during the first-week
post-enrolment for cows enrolled at different stages of lactation (Fresh (a), Early Lactation (b) or Late Lactation (c)). Adjusted means ±
standard error of the mean presented here was obtained for the interaction term stage of lactation by lameness at enrolment by treatment
group. Levels within a variable with different letters are statistically significantly different (honestly significant difference test. p < 0.05)
T A B L E 4 Results from multivariable linear regression model



















being 45.35 ± 0.71 and 42.37 ± 0.87 kg per day respec-
tively (p < 0.01). The effect of ketoprofen administra-
tion was more prominent on cows that were freshly
calved and lame at enrolment. These cows produced
58.38 ± 1.85 kg per day the week after treatment if they
were in the ketoprofen treatment group comparing to
the control ones that produced 47.89 ± 1.81 kg per day
(p < 0.05).
DISCUSSION
Our study shows that administering ketoprofen when
treating cows with DD may have beneficial effects on
their mobility and their milk production especially if
animals are visibly lame when treated. In a recent
‘expert opinion’ survey it was reported that nine out
of 12 experts would recommend the use of NSAIDs for
the treatment of active DD but most of them would
reserve this for cows with a mobility score of 3.12
Importantly, the decision regarding this matter could
not be evidence-based as there has been no published
study investigating this so far. Our study provides the
first evidence of possible welfare and production ben-
efits associated with the use of NSAIDs when treating
active DD lesions.
Our study showed potential benefits of ketoprofen
administration on animals’ mobility 1-week post-
treatment. The effect of treatment on lameness 1-week
post-treatment was not statistically significant when
the whole study population was considered (p= 0.097)
but a numeric difference was observed. This effect was
more prominent when only lame at enrolment ani-
mals were considered. Only 20 animals were included
in this analysis and therefore results should be treated
cautiously. A follow-up study focusing on enrolling
more cows affected with DD and with a mobility score
greater than 1 is warranted. Similar findings have been
reported for lameness or non-infectious lameness
causing lesions but this is the first time this is shown
for DD lesions specifically. Previous studies have
shown positive outcomes of administering ketoprofen
in the treatment of claw horn lesions14; positive effects
on animal behaviour were also shown.17 Whay et al.18
have also shown positive effects of ketoprofen admin-
istered to lame cows. Other studies that dealt with
the use of NSAIDs, such as flunixin meglumine19 and
tolfenamic acid20 in the treatment of lameness have
shown contradicting results. Chapel et al.19 did not
report an effect of flunixin meglumine administration
on cattle locomotion scores post trimming. Laven
et al.20 did show improvements in locomotion scores
of lame cows treated with tolfenamic acid.
The pain generated by DD negatively affects the
animals’ behaviour and productivity,21 both directly
and indirectly through a decrease in dry matter
intake. It has been shown that lame cattle consume
less feed and produce less milk than their non-
lame counterparts.22 The consumption of sufficient
amounts of dry matter is particularly important for
periparturient animals. If cows develop DD and, even
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more importantly, become lame in the periparturient
period they will suffer production loss possibly due to
reduced dry matter intakes.23 We believe that at this
last point lies the reason why the administration of
ketoprofen had such a significant effect on the milk
production of the DD affected, lame animals, espe-
cially for freshly calved animals. On the basis that the
treatment of DD should also have a focus on limiting
production losses, the administration of ketoprofen
appears very promising. The potential welfare bene-
fits could be enough to justify the use of ketoprofen.
However, the possible milk production benefits may
also offer economic benefits to the farmer (especially
given the fact that administration of ketoprofen does
not require a milk withdrawal period in the UK) and
therefore may make it more likely for such a treat-
ment approach to be adopted. It should however be
noted that a comprehensive cost-benefit analysis was
beyond the scope of our study.
Our study has limitations that should be taken
into consideration when interpreting its findings.
As already stated in the materials and methods sec-
tion, the researcher performing mobility scoring did
not administer treatments but was responsible for
updating farmers’ records and therefore may not
be considered entirely masked to treatment when
performing mobility scoring 1-week post-enrolment.
However, given the fact that mobility scoring was
happening one week later and while sorting a large
number of cows for a different project we believe that
the chances this scorer would actually remember cer-
tain cows and their treatment are very low. In any case,
this potential issue could not have affected the results
associated with milk production. Another possible
study limitation is the fact that some of the enrolled
cows were affected by DD and sole ulceration or white
line disease. Ketoprofen effects for these animals
could be associated with the presence of these other
lesions. The presence of sole ulceration or white line
disease was included in our multivariable analysis
and therefore the treatment effect we describe in this
model was corrected for the effects of these lesions.
Furthermore, we did run our analysis excluding cows
with sole ulceration and white line disease and still
obtained very similar results. Due to the way this study
was run we were unable to administer a three-day
course of ketoprofen and were only able to perform
one mobility scoring a week post-treatment. Potential
benefits of ketoprofen administration could have been
better realised had we been able to administer more
than one dose and monitor animals more intensively.
Finally, based on initial planning (based on the num-
ber of animals enrolled in the main project and our
existing knowledge of active DD incidence rates on
the collaborating farms), we were aiming to enrol at
least 250 animals in this study. Due to the COVID-19
pandemic breaking out while the study was ongoing,
visits to the farms had to be halted. This resulted in the
reduction of our sample size to 158 animals. This is still
an acceptable sample size and did allow us to detect
statistically significant differences (results regarding
daily milk yield); however, a larger sample size would
have increased the power of our study. This also led
to the treatment and control groups being unbal-
anced which is another limitation that needs to be
considered.
CONCLUSION
This randomised positively controlled clinical trial
suggests that the addition of ketoprofen in the treat-
ment of active DD lesions may be beneficial for ani-
mal welfare as it was associated with an improvement
in mobility scores and for animal productivity as it was
associated with an increased daily milk production (at
least for the first few days post-treatment).
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